Drugs / D113
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05089279 | Nov 2021 → Jan 2022 | heart failure | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT04952506 | Jul 2021 | chronic renal failure syndrome | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | D113 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04952506 ↗ |
| Route | Oral | “QD, PO” NCT05089279 ↗ |